INCY – Incyte Corporation

Incyte Corporation

INCY

$71.93

Name : Incyte Corporation

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $13,857,314,816.00

EPSttm : 0.09

Incyte Corporation

$71.93

0.75%

$0.54

Float Short %

2.69

Margin Of Safety %

Put/Call OI Ratio

0.39

EPS Next Q Diff

-0.03

EPS Last/This Y

-1.37

EPS This/Next Y

4.75

Price

71.95

Target Price

78.38

Analyst Recom

2.24

Performance Q

8.7

Relative Volume

0.5

Beta

0.69

Ticker: INCY

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2024-12-19	INCY	67	0.36	0.32	48208
2024-12-20	INCY	68.91	0.37	0.51	48329
2024-12-23	INCY	69.86	0.35	0.29	22000
2024-12-24	INCY	69.91	0.35	0.58	23220
2024-12-26	INCY	69.5	0.35	0.03	23349
2024-12-27	INCY	69.23	0.34	0.10	23448
2024-12-30	INCY	68.42	0.34	0.08	23559
2024-12-31	INCY	69.09	0.34	0.46	23617
2025-01-02	INCY	69.51	0.34	3.02	23710
2025-01-03	INCY	69.61	0.34	0.15	23622
2025-01-06	INCY	71.9	0.34	0.18	23847
2025-01-07	INCY	73.21	0.33	0.10	25623
2025-01-08	INCY	73.13	0.31	0.01	27591
2025-01-09	INCY	73.13	0.31	0.01	27591
2025-01-10	INCY	70.52	0.30	0.08	28400
2025-01-13	INCY	72.4	0.29	3.17	28918
2025-01-14	INCY	71.94	0.34	0.09	30035
2025-01-15	INCY	72.45	0.34	1.01	30649
2025-01-16	INCY	72.45	0.37	0.89	31984
2025-01-17	INCY	71.95	0.39	0.81	32715
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2024-12-19	INCY	67.03	46.3	1133.3	1.30
2024-12-20	INCY	69.07	46.3	1195.9	1.30
2024-12-23	INCY	69.84	46.3	1168.7	1.30
2024-12-24	INCY	69.91	46.3	1148.2	1.30
2024-12-26	INCY	69.56	46.3	1138.5	1.30
2024-12-27	INCY	69.21	46.3	1138.4	1.30
2024-12-30	INCY	68.39	46.3	1126.8	1.30
2024-12-31	INCY	69.07	46.3	1162.2	1.30
2025-01-02	INCY	69.51	46.3	1157.1	1.30
2025-01-03	INCY	69.60	46.3	1148.2	1.30
2025-01-06	INCY	71.87	46.3	1199.2	1.30
2025-01-07	INCY	73.21	46.3	1176.0	1.30
2025-01-08	INCY	73.13	46.3	1145.3	1.30
2025-01-09	INCY	73.13	46.3	1146.6	1.30
2025-01-10	INCY	70.50	46.3	1088.2	1.30
2025-01-13	INCY	72.40	46.3	1189.6	1.30
2025-01-14	INCY	71.96	46.3	1137.4	1.30
2025-01-15	INCY	72.46	46.3	1158.6	1.30
2025-01-16	INCY	72.48	46.3	1147.1	1.30
2025-01-17	INCY	71.95	46.3	1135.0	1.30
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2024-12-19	INCY	-1.82	-9.00	3.16
2024-12-20	INCY	-1.82	-9.00	3.16
2024-12-23	INCY	-1.77	-8.99	3.16
2024-12-24	INCY	-1.77	-8.99	3.16
2024-12-26	INCY	-1.82	-8.99	3.09
2024-12-27	INCY	-1.82	-8.99	3.09
2024-12-30	INCY	-1.83	-9.02	3.09
2024-12-31	INCY	-1.83	-9.02	3.09
2025-01-02	INCY	-1.80	-9.02	3.09
2025-01-03	INCY	-1.82	-9.02	3.09
2025-01-06	INCY	-1.81	-9.07	3.09
2025-01-07	INCY	-1.81	-9.07	3.09
2025-01-08	INCY	-1.82	-9.07	3.09
2025-01-09	INCY	-1.82	-9.07	3.09
2025-01-10	INCY	-1.82	-9.07	3.09
2025-01-13	INCY	-1.56	-9.04	2.69
2025-01-14	INCY	-1.56	-9.04	2.69
2025-01-15	INCY	-1.53	-9.04	2.69
2025-01-16	INCY	-1.53	-9.04	2.69
2025-01-17	INCY	-1.53	-9.04	2.69
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

1.07

Avg. EPS Est. Current Quarter

1.55

Avg. EPS Est. Next Quarter

1.04

Insider Transactions

-1.53

Institutional Transactions

-9.04

Beta

0.69

Average Sales Estimate Current Quarter

1143

Average Sales Estimate Next Quarter

1003

Fair Value

101.34

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

34.8

Max Drawdown 5-Year %

-53.3

Target Price

78.38

P/E

509.42

Forward P/E

12.11

PEG

26.71

P/S

3.4

P/B

4.37

P/Free Cash Flow

451.38

EPS

0.14

Average EPS Est. Cur. Y

1.3

EPS Next Y. (Est.)

6.06

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

0.8

Relative Volume

0.5

Return on Equity vs Sector %

-18.1

Return on Equity vs Industry %

-5.5

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.01

EBIT Estimation

1135

Incyte Corporation

Sector: Healthcare

Industry: Biotechnology

Employees: 2524

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

stock quote shares INCY – Incyte Corporation Stock Price stock today

news today INCY – Incyte Corporation stock forecast ,stock prediction 2023 2024 2025

marketwatch INCY – Incyte Corporation yahoo finance google finance

stock history INCY – Incyte Corporation invest stock market

stock prices INCY premarket after hours

ticker INCY fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

INCY – Incyte Corporation

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: INCY

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y